Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06088888 · ClinicalTrials.gov registry record · Phase 1
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
A Phase 1 study of Chronic Myelogenous Leukemia, sponsored by Shenzhen TargetRx Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 2
- Study locations
NCT06088888 is a Phase 1 study of Chronic Myelogenous Leukemia that is actively recruiting participants, run by Shenzhen TargetRx Co.. The registered enrollment target is 90 participants, below the 280-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06088888, a Phase 1 study of Chronic Myelogenous Leukemia, is actively recruiting participants, sponsored by Shenzhen TargetRx Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.
Conditions Studied
Interventions
- DRUG TGRX-678
Study Locations (2)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06088888
The ClinicalTrials.gov registry entry for NCT06088888 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 29 other Chronic Myelogenous Leukemia trials with a reported enrollment target (68% lower). The listed sponsor is Shenzhen TargetRx Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Myelogenous Leukemia appearing as the primary indexed condition, and to 1 intervention - of which TGRX-678 is the first listed.
NCT06088888 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Washington.
Frequently Asked Questions
What is clinical trial NCT06088888 about?
NCT06088888 is a clinical study titled "TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia". The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.
What is the current status of trial NCT06088888?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2024-07-02. Estimated completion is 2027-06-30.
What conditions does trial NCT06088888 study?
This clinical trial studies the following conditions: Chronic Myelogenous Leukemia.
What interventions are being tested in trial NCT06088888?
The interventions under investigation include: TGRX-678 (DRUG).
Who is sponsoring clinical trial NCT06088888?
This trial is sponsored by Shenzhen TargetRx Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06088888 being conducted?
This trial has 2 study locations across Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelogenous Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
RECRUITING · Phase 1
-
Administration of Donor T Cells With the Caspase-9 Suicide Gene
ACTIVE NOT RECRUITING · Phase 1
-
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers
COMPLETED · Phase 1
-
Improving Blood Stem Cell Collection and Transplant Procedures
COMPLETED · Phase 1
-
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies
COMPLETED · Phase 1
-
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.